Evangelia Razis

3.3k total citations
77 papers, 1.6k citations indexed

About

Evangelia Razis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Evangelia Razis has authored 77 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Evangelia Razis's work include HER2/EGFR in Cancer Research (21 papers), Cancer Treatment and Pharmacology (15 papers) and Breast Cancer Treatment Studies (11 papers). Evangelia Razis is often cited by papers focused on HER2/EGFR in Cancer Research (21 papers), Cancer Treatment and Pharmacology (15 papers) and Breast Cancer Treatment Studies (11 papers). Evangelia Razis collaborates with scholars based in Greece, United States and Italy. Evangelia Razis's co-authors include George Fountzilas, Stefanos Labropoulos, Dimosthenis Skarlos, Christos Christodoulou, Mattheos Bobos, Pavlos Papakostas, Helen Gogas, Haralabos P. Kalofonos, Dimitrios Pectasides and Jonathan A. Fletcher and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Evangelia Razis

76 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Evangelia Razis Greece	23	1.0k	417	412	252	232	77	1.6k
José Luís Passos‐Coelho Portugal	21	913 0.9×	288 0.7×	273 0.7×	281 1.1×	179 0.8×	46	1.4k
Roberta Camisa Italy	17	872 0.9×	289 0.7×	448 1.1×	290 1.2×	535 2.3×	44	1.5k
Vernon Harvey New Zealand	22	1.3k 1.3×	357 0.9×	258 0.6×	489 1.9×	312 1.3×	44	1.8k
Henry G. Kaplan United States	22	831 0.8×	325 0.8×	233 0.6×	396 1.6×	146 0.6×	79	1.6k
Maysa Abu‐Khalaf United States	23	986 1.0×	312 0.7×	350 0.8×	614 2.4×	168 0.7×	91	1.8k
Gisela Schwab United States	13	644 0.6×	352 0.8×	361 0.9×	126 0.5×	334 1.4×	23	1.3k
Francisco Ayala Spain	24	774 0.8×	240 0.6×	492 1.2×	352 1.4×	233 1.0×	105	2.0k
Diana Lake United States	22	1.2k 1.2×	452 1.1×	337 0.8×	465 1.8×	289 1.2×	70	1.7k
Claudio Zamagni Italy	26	1.2k 1.2×	464 1.1×	416 1.0×	573 2.3×	335 1.4×	148	2.1k
Iuliana Shapira United States	20	787 0.8×	247 0.6×	244 0.6×	442 1.8×	191 0.8×	53	1.6k

Countries citing papers authored by Evangelia Razis

Since Specialization

Citations

This map shows the geographic impact of Evangelia Razis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evangelia Razis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evangelia Razis more than expected).

Fields of papers citing papers by Evangelia Razis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evangelia Razis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evangelia Razis. The network helps show where Evangelia Razis may publish in the future.

Co-authorship network of co-authors of Evangelia Razis

This figure shows the co-authorship network connecting the top 25 collaborators of Evangelia Razis. A scholar is included among the top collaborators of Evangelia Razis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evangelia Razis. Evangelia Razis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Reilly, Seamus, Lisa Fox, R. M. O'Leary, et al.. (2025). Climate change impacts and sustainability integration among breast international group members. The Breast. 81. 104469–104469. 1 indexed citations

O’Reilly, Séamus, Inês Vaz-Luís, Virginie Adam, et al.. (2025). Advancing equitable access to innovation in breast cancer. npj Breast Cancer. 11(1). 71–71. 1 indexed citations

Giannoudis, Athina, Ethan Sokol, Evangelia Razis, et al.. (2024). Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors. npj Precision Oncology. 8(1). 282–282. 4 indexed citations

Ignatiadis, Michail, Emmanouil Saloustros, Ciara M. Kelly, et al.. (2024). 338TiP EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). Annals of Oncology. 35. S355–S356. 2 indexed citations

Kaklamanis, Loukas, Helena Linardou, Evangelia Razis, et al.. (2024). Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs. Frontiers in Oncology. 14. 1435559–1435559. 1 indexed citations

Nicolatou‐Galitis, Ourania, Amanda Psyrri, Nikolaos Tsoukalas, et al.. (2023). Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients. SHILAP Revista de lepidopterología. 3(1). 123–133. 2 indexed citations

Giannoudis, Athina, Ethan Sokol, Shakti Ramkissoon, et al.. (2023). Abstract P5-14-10: Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases. Cancer Research. 83(5_Supplement). P5–14. 1 indexed citations

Weller, Michael, Émilie Le Rhun, Martin J. van den Bent, et al.. (2023). Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. Neuro-Oncology. 25(7). 1200–1224. 23 indexed citations

Labropoulos, Stefanos, et al.. (2021). The Value of New Fields in the Medical Record for Quality Improvement. SHILAP Revista de lepidopterología. 4(2). 65–69. 1 indexed citations

10.

Razis, Evangelia, Georgia-Angeliki Koliou, Eleftheria Tsolaki, et al.. (2021). Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer. Anticancer Research. 41(4). 1793–1802. 6 indexed citations

11.

Tsiotos, Gregory G., Nikiforos Ballian, Theodoros Michelakos, et al.. (2019). Portal-Mesenteric Vein Resection in Borderline Pancreatic Cancer; 33 Month-Survival in Patients with Good Performance Status. SHILAP Revista de lepidopterología. 5(1). 43–50. 7 indexed citations

12.

Peters, Katherine B., et al.. (2019). Neurooncology Research in Nigeria: Great Untapped Potential. World Neurosurgery. 124. 381–385. 6 indexed citations

13.

Kotoula, Vassiliki, Kalliopi Tsakiri, Georgia-Angeliki Koliou, et al.. (2018). Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. Clinical Breast Cancer. 19(2). 113–125.e4. 8 indexed citations

14.

Koumarianou, Anna, Georgia Karayannopoulou, Anna Batistatou, et al.. (2015). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. Cancer Chemotherapy and Pharmacology. 75(6). 1289–1301. 4 indexed citations

15.

Pavlakis, Kitty, Mattheos Bobos, Anna Batistatou, et al.. (2014). p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab. Pathology & Oncology Research. 21(2). 273–282. 5 indexed citations

16.

Fountzilas, George, Vassiliki Kotoula, Dimitrios Pectasides, et al.. (2013). Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial. PLoS ONE. 8(7). e69256–e69256. 11 indexed citations

17.

Razis, Evangelia, Mattheos Bobos, Vassiliki Kotoula, et al.. (2011). Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Research and Treatment. 128(2). 447–456. 137 indexed citations

18.

Koutras, Αngelos, Konstantine T. Kalogeras, Meletios Α. Dimopoulos, et al.. (2008). Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. British Journal of Cancer. 99(11). 1775–1785. 53 indexed citations

19.

Fountzilas, George, George P. Stathopoulos, George Kouvatseas, et al.. (2004). Adjuvant Cytotoxic and Endocrine Therapy in Pre- and Postmenopausal Patients With Breast Cancer and One to Nine Infiltrated Nodes. American Journal of Clinical Oncology. 27(1). 57–67. 1 indexed citations

20.

Fountzilas, George, Evangelia Razis, D. Tsavdaridis, et al.. (2003). Continuation of Trastuzumab Beyond Disease Progression Is Feasible and Safe in Patients with Metastatic Breast Cancer: A Retrospective Analysis of 80 Cases by the Hellenic Cooperative Oncology Group. Clinical Breast Cancer. 4(2). 120–125. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact